Healthy VolunteerSWEETNCT06997133
Sucralose as a Way to Enhance Regulatory T Cells
A study testing sucralose in people with Healthy Volunteer, run by Caroline Lamarche at 1 site in Canada.
Trial summary
Title: Taking the SWEET approach to protect the transplanted kidney. Background: Kidneys are essential organs in our body. When they do not work, patients require machines to help them or receive a new kidney from a donor (transplantation) to survive. Thus far, transplantation is the best treatment. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteer
- What is being tested?
- sucralose
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 10 participants
- Where
- 1 siteCanada
- Study dates
- 1 Sep 2025to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Body weight comparable to average reported in Canada
Who cannot join
- Past medical history of autoimmune disease
- The use of any regular medication except contraceptive pills
- Pregnant women
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
Centre de recherche de l'Hôpital Maisonneuve-Rosemont
Montreal, Quebec, H1T2M4
Caroline Lamarche, MD, MSc, 514-252-3400 ext. 8682, caroline.lamarche.1@umontreal.ca
Caroline Lamarche, MD, MSc
About this study
Official title: Sucralose as a Way to Enhance Regulatory T Cells: The Sweet Trial
Title: Taking the SWEET approach to protect the transplanted kidney.
Background: Kidneys are essential organs in our body. When they do not work, patients require machines to help them or receive a new kidney from a donor (transplantation) to survive. Thus far, transplantation is the best treatment. However, the immune system will recognize the new kidney as foreign and try to destroy it, which is called kidney rejection. To prevent rejection, patients with kidney transplants depend on drugs to suppress the immune system. However, these drugs have many side effects, including the risk of infection, cancer, and diabetes.
Read more
The immune system is made of many different types of cells. One cell type in particular is T cells that, when kept unchecked, will attack the kidney transplant. However, there is a small subset of these T cells called regulatory T cells (Tregs) that police the immune system and aid in accepting the new kidney. Current ways to increase these police cells (Tregs) after a transplant are expensive and not widely available. Therefore, there is a need to find a better and more accessible way to increase Treg numbers after a transplant to increase the longevity of the newly transplanted kidney.
What we eat is critical in shaping the immune system. Artificial sweeteners, like sucralose (found in Splenda), are often used as a sugar substitute. They are low in calories and safe to consume. However, recent studies suggest they may have unexpected effects on the body. Research in mice has shown that sucralose impacts the immune system. Specifically, the investigators have found that it could suppress T cells that could cause kidney rejection while increasing the Tregs (the police).
Given these findings, the investigators hypothesize that sucralose could be beneficial in conditions where dampening the immune system is desirable, such as in the case of transplantation. By boosting Tregs and reducing the anti-transplant T cells, sucralose may help to protect against organ rejection.
Purpose: The goal of this study is thus to test whether sucralose can safely and effectively modulate the immune system in humans.
Method: The investigator propose to test the impact of sucralose on the immune system. This pilot study will test the effect of sucralose in 10 healthy volunteers. The participants will take sucralose or placebo as a pill twice daily for a month. Healthy volunteers will then stop for a two weeks (washout period). After the washout period, the volunteers on sucralose will switch to placebo, while the placebo group will switch to sucralose pills for one more months. The investigators will take blood samples at the beginning, after one month, after the washout and at the end of the study to study how the immune system changes.
Anticipated outcomes: The investigators expect that sucralose will impact the immune system and increase the number of regulatory T cells.
Relevance to patient/community: Artificial sweeteners are commonly used in the food and pharmaceutical industries. However, their impact on the immune system has not been thoroughly investigated in humans.
Conclusion: Kidney transplantation is the most effective treatment for kidney failure, but the immune system's rejection of the transplanted organ remains a major challenge. Current immunosuppressive drugs used to prevent rejection have significant side effects, underscoring the need for safer alternatives. The investigator research suggests that sucralose, a widely used artificial sweetener, may offer a novel solution by increasing the good T cells (Tregs) and reducing harmful T cells that contribute to rejection. This pilot study will explore sucralose's potential to modulate the immune system in humans, potentially leading to improved transplant outcomes and broader implications for immune regulation.
- Conditions
- Healthy Volunteer
- Being tested
- sucralose, Placebo
- Keywords
- sucralose, immune system, regulatory T cells, metabolomic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sucraloseDietary supplement
Encapsulated sucralose po BID
PlaceboOther
Encapsulated lactose po bid
| Study group | Role | What they receive |
|---|---|---|
| Starting with placebo - washout - sucralose. | Placebo comparator | This group will start with a placebo (4 weeks) , then will have a washout period (2 weeks) and then will test sucralose (4 weeks) Receives: Dietary Supplement: sucralose; Other: Placebo |
| Starting with sucralose - washout - placebo. | Active comparator | This group will start with sucralose (4 weeks) , then will have a washout period (2 weeks) and then will test the placebo (4 weeks) Receives: Dietary Supplement: sucralose; Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Regulatory T cells
Change in % regulatory T cells on total CD4+ T cells compared to baseline
Measured: After 4 weeks on sucralose and placebo.
Secondary outcomes (4)
T cell cytokine production (TNFa, IFNy, IL2)
% cytokine production o CD4+ and CD8+ T cells
Measured: 4 weeks compared to baseline on either placebo or sucralose
Frequency of immune populations in the blood (CD4+, CD8+, NK, B cells, CD11b myeloid cells)
% of CD45+ cells (total immune marker)
Measured: 4 weeks compared to baseline on either sucralose or placebo
Frequency of CD4+ T cells lineages
% RORyt, T-bet, GATA3 on CD4+ T cells
Measured: 4 weeks compared to baseline on sucralose or placebo
Frequency of naive, central and effector memory or terminally differentiated CD4+ and CD8+ T cells
% of CD62L+CD45RA+CD45RO- (naive), CD62L+CD45RO+CD44+CD45RA- (central memory), CD62L-CD45RA-CD45RO+CD44+ (effector memory) and CD62L-CD45RA+CD45RO (terminally differentiated cells) on both CD4+ and CD8+ T cells
Measured: 4 weeks compared to baseline on both sucralose or placebo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2025
- Study start1 Sep 2025 (estimated)
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Healthy VolunteerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Caroline Lamarche
- Sponsor type
- University, hospital or other
- Collaborators
- Ciusss de L'Est de l'Île de Montréal
- Responsible party
- Sponsor-investigator, Caroline Lamarche, Ciusss de L'Est de l'Île de Montréal
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06997133
- Sponsor's protocol ID
- 2025-3912
- Acronym
- SWEET
- Status last verified
- Jan 2025
- First submitted
- 20 Dec 2024
- Last updated
- 5 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Bourguignon L, Benazzouk Y, Bokou-Gianneli E, Zani F, Blagih J, Lamarche C. Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol. Can J Kidney Health Dis. 2026 Feb 13;13:20543581261418540. doi: 10.1177/20543581261418540. eCollection 2026.
PubMed 41694241
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sucralose as a Way to Enhance Regulatory T Cells: The Sweet Trial
- ClinicalTrials.gov ID
- NCT06997133
- Acronym / sponsor ID
- SWEET / 2025-3912
- Conditions
- Healthy Volunteer
- Keywords
- sucralose, immune system, regulatory T cells, metabolomic
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Caroline LamarcheUniversity, hospital or other
- Collaborators
- Ciusss de L'Est de l'Île de Montréal
- Study start
- 1 Sep 2025 (estimated)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 30 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Title: Taking the SWEET approach to protect the transplanted kidney.
Background: Kidneys are essential organs in our body. When they do not work, patients require machines to help them or receive a new kidney from a donor (transplantation) to survive. Thus far, transplantation is the best treatment. However, the immune system will recognize the new kidney as foreign and try to destroy it, which is called kidney rejection. To prevent rejection, patients with kidney transplants depend on drugs to suppress the immune system. However, these drugs have many side effects, including the risk of infection, cancer, and diabetes.
The immune system is made of many different types of cells. One cell type in particular is T cells that, when kept unchecked, will attack the kidney transplant. However, there is a small subset of these T cells called regulatory T cells (Tregs) that police the immune system and aid in accepting the new kidney. Current ways to increase these police cells (Tregs) after a transplant are expensive and not widely available. Therefore, there is a need to find a better and more accessible way to increase Treg numbers after a transplant to increase the longevity of the newly transplanted kidney.
What we eat is critical in shaping the immune system. Artificial sweeteners, like sucralose (found in Splenda), are often used as a sugar substitute. They are low in calories and safe to consume. However, recent studies suggest they may have unexpected effects on the body. Research in mice has shown that sucralose impacts the immune system. Specifically, the investigators have found that it could suppress T cells that could cause kidney rejection while increasing the Tregs (the police).
Given these findings, the investigators hypothesize that sucralose could be beneficial in conditions where dampening the immune system is desirable, such as in the case of transplantation. By boosting Tregs and reducing the anti-transplant T cells, sucralose may help to protect against organ rejection.
Purpose: The goal of this study is thus to test whether sucralose can safely and effectively modulate the immune system in humans.
Method: The investigator propose to test the impact of sucralose on the immune system. This pilot study will test the effect of sucralose in 10 healthy volunteers. The participants will take sucralose or placebo as a pill twice daily for a month. Healthy volunteers will then stop for a two weeks (washout period). After the washout period, the volunteers on sucralose will switch to placebo, while the placebo group will switch to sucralose pills for one more months. The investigators will take blood samples at the beginning, after one month, after the washout and at the end of the study to study how the immune system changes.
Anticipated outcomes: The investigators expect that sucralose will impact the immune system and increase the number of regulatory T cells.
Relevance to patient/community: Artificial sweeteners are commonly used in the food and pharmaceutical industries. However, their impact on the immune system has not been thoroughly investigated in humans.
Conclusion: Kidney transplantation is the most effective treatment for kidney failure, but the immune system's rejection of the transplanted organ remains a major challenge. Current immunosuppressive drugs used to prevent rejection have significant side effects, underscoring the need for safer alternatives. The investigator research suggests that sucralose, a widely used artificial sweetener, may offer a novel solution by increasing the good T cells (Tregs) and reducing harmful T cells that contribute to rejection. This pilot study will explore sucralose's potential to modulate the immune system in humans, potentially leading to improved transplant outcomes and broader implications for immune regulation.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Starting with placebo - washout - sucralose. | Placebo comparator | Dietary Supplement: sucralose, Other: PlaceboThis group will start with a placebo (4 weeks) , then will have a washout period (2 weeks) and then will test sucralose (4 weeks) |
| Starting with sucralose - washout - placebo. | Active comparator | Dietary Supplement: sucralose, Other: PlaceboThis group will start with sucralose (4 weeks) , then will have a washout period (2 weeks) and then will test the placebo (4 weeks) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Body weight comparable to average reported in Canada
Key exclusion criteria (3 listed)
- Past medical history of autoimmune disease
- The use of any regular medication except contraceptive pills
- Pregnant women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sucraloseEncapsulated sucralose po BID | Dietary supplement | Starting with placebo - washout - sucralose., Starting with sucralose - washout - placebo. |
| PlaceboEncapsulated lactose po bid | Other | Starting with placebo - washout - sucralose., Starting with sucralose - washout - placebo. |
Primary outcome
Regulatory T cells
Time frame: After 4 weeks on sucralose and placebo.
Change in % regulatory T cells on total CD4+ T cells compared to baseline
4 secondary outcomes
T cell cytokine production (TNFa, IFNy, IL2)
Time frame: 4 weeks compared to baseline on either placebo or sucralose
Frequency of immune populations in the blood (CD4+, CD8+, NK, B cells, CD11b myeloid cells)
Time frame: 4 weeks compared to baseline on either sucralose or placebo
Frequency of CD4+ T cells lineages
Time frame: 4 weeks compared to baseline on sucralose or placebo
Frequency of naive, central and effector memory or terminally differentiated CD4+ and CD8+ T cells
Time frame: 4 weeks compared to baseline on both sucralose or placebo
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2025.
- Derived from this study: PubMed 41694241Bourguignon L, Benazzouk Y, Bokou-Gianneli E, Zani F, Blagih J, Lamarche C. Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol. Can J Kidney Health Dis. 2026 Feb 13;13:20543581261418540. doi: 10.1177/20543581261418540. eCollection 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Volunteer
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Not yet recruitingObservational study
Screening Protocol
Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing sucralose in people with Healthy Volunteer, run by Caroline Lamarche at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Caroline Lamarche, MD, MSc (514-252-3400 ext. 8682, caroline.lamarche.1@umontreal.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Regulatory T cells (time frame: After 4 weeks on sucralose and placebo.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06997133, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.